- Home
- MRT vs VNDA Comparison
MRT vs VNDA Comparison
Compare MRT & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRT
- VNDA
- Stock Information
- Founded
- MRT 2018
- VNDA 2002
- Country
- MRT Turkey
- VNDA United States
- Employees
- MRT N/A
- VNDA N/A
- Industry
- MRT Rental/Leasing Companies
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- MRT Consumer Discretionary
- VNDA Health Care
- Exchange
- MRT Nasdaq
- VNDA Nasdaq
- Market Cap
- MRT 228.0M
- VNDA 249.4M
- IPO Year
- MRT N/A
- VNDA 2006
- Fundamental
- Price
- MRT $2.41
- VNDA $5.43
- Analyst Decision
- MRT Strong Buy
- VNDA Strong Buy
- Analyst Count
- MRT 2
- VNDA 2
- Target Price
- MRT $6.00
- VNDA $16.50
- AVG Volume (30 Days)
- MRT 171.8K
- VNDA 444.8K
- Earning Date
- MRT 08-08-2018
- VNDA 11-05-2025
- Dividend Yield
- MRT N/A
- VNDA N/A
- EPS Growth
- MRT N/A
- VNDA N/A
- EPS
- MRT N/A
- VNDA N/A
- Revenue
- MRT $24,577,378.00
- VNDA $203,467,000.00
- Revenue This Year
- MRT $83.87
- VNDA $15.45
- Revenue Next Year
- MRT $115.34
- VNDA $37.82
- P/E Ratio
- MRT N/A
- VNDA N/A
- Revenue Growth
- MRT 29.67
- VNDA 11.78
- 52 Week Low
- MRT $1.77
- VNDA $3.81
- 52 Week High
- MRT $3.89
- VNDA $5.55
- Technical
- Relative Strength Index (RSI)
- MRT 53.42
- VNDA 71.64
- Support Level
- MRT $1.97
- VNDA $4.84
- Resistance Level
- MRT $2.45
- VNDA $5.17
- Average True Range (ATR)
- MRT 0.16
- VNDA 0.20
- MACD
- MRT 0.00
- VNDA 0.07
- Stochastic Oscillator
- MRT 83.02
- VNDA 95.54
About MRT Marti Technologies Inc.
Marti Technologies Inc is a mobility app, offering multiple transportation services to its riders. Marti operates a ride-hailing service that matches riders with car, motorcycle, and taxi drivers, and operates a large fleet of rental e-mopeds, e-bikes, and e-scooters. All of Marti's offerings are serviced by proprietary software systems and IoT infrastructure.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.